XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
shares in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
contract
position
shares
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
contract
segment
position
shares
Jun. 30, 2024
USD ($)
shares
Dec. 31, 2024
USD ($)
Jan. 31, 2010
cvr
Property, Plant and Equipment            
Number of operating segments | segment     1      
Number of reportable segments | segment     1      
Revenue recognized that was previously deferred $ 300,000 $ 500,000 $ 600,000 $ 1,000,000    
Sale of Viking common stock (in shares) | shares 0.0   0.0 0.7    
Gain on sale of Viking common stock       $ 60,000,000    
Number of positions in an unrealized loss position | position 61   61      
Unrealized losses $ (60,000.00)   $ (60,000.00)      
Credit losses related to available-for-sale debt securities 0   0      
Amortized cost   50,000.00   50,000.00    
Increase (decrease) in allowance for credit losses 100,000 200,000 400,000 (100,000)    
Inventory write-down 0 200,000 0 200,000    
Inventory 15,489,000   15,489,000   $ 14,114,000  
Fair value adjustments to partner program derivatives (1,276,000) 0 (833,000) 0    
Gain on derivative instrument   1,200,000   1,200,000    
Losses from equity method investment in Primrose Bio     0 10,382,000    
Observable price changes $ 0 (25,800,000) $ 0 (25,800,000)    
Primrose mRNA            
Property, Plant and Equipment            
Investment owned, net assets, percentage 31.40%   31.40%   31.40%  
Losses from equity method investment in Primrose Bio   2,200,000   4,600,000    
Equity method investments         $ 0  
Impairment of equity method investment $ 0 (5,800,000) $ 0 (5,800,000)    
Vikings            
Property, Plant and Equipment            
Fair value adjustments to partner program derivatives   15,200,000   15,200,000    
Performance Shares            
Property, Plant and Equipment            
Performance period for awards (in years)     3 years      
Metabasis Therapeutics            
Property, Plant and Equipment            
Number of contingent value rights issued | cvr           4
Minimum | Performance Shares            
Property, Plant and Equipment            
Payout range (as a percent)     0.00%      
Maximum | Performance Shares            
Property, Plant and Equipment            
Payout range (as a percent)     200.00%      
Partner Programs            
Property, Plant and Equipment            
Fair value adjustments to partner program derivatives $ 1,200,000   $ 600,000      
Agenus Partnered Program            
Property, Plant and Equipment            
Percentage of milestones (as a percent) 50.00%   50.00%      
Agenus Partnered Program | Primordial Genetics            
Property, Plant and Equipment            
Number of contracts | contract 2   2      
Agenus, Inc.            
Property, Plant and Equipment            
Fair value adjustments to partner program derivatives $ 800,000   $ (500,000)      
Gain on derivative instrument   100,000   100,000    
Primrose mRNA            
Property, Plant and Equipment            
Fair value adjustments to partner program derivatives (700,000)   (600,000)      
Gain on derivative instrument   $ 200,000   $ 400,000    
Castle Creek Investment            
Property, Plant and Equipment            
Fair value adjustments to partner program derivatives 300,000   300,000      
Captisol            
Property, Plant and Equipment            
Inventory $ 2,600,000   $ 2,600,000   $ 3,100,000